Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ionis Pharmaceuticals (IONS)
Ionis told investors in July that TRYNGOLZA was "on track" for $100 million to $110 million in 2026 sales. On November 9, it lowered that target to roughly $50 million. NEW YORK, Nov. 9, 2026 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today cut its full-year TRYNGOLZA...
Covered in this story
Analyst targets on Ionis Pharmaceuticals
- BMO Capital Markets: $44.3 → $66 by Oct 2027 · Outperform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $IONS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ionis Pharmaceuticals →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.